Progression parameters for emphysema: A clinical investigation  by Stolk, Jan et al.
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 1924–19300954-6111/$ - see fr
doi:10.1016/j.rmed.
Corresponding au
E-mail address: jProgression parameters for emphysema:
A clinical investigation
Jan Stolka,, Hein Putterb, Els M. Bakkerc, Saher B. Shakerd, David G. Parre,
Eeva Piitulainenf, Erich W. Russig, Elzbieta Grebskig, Asger Dirksend,
Robert A. Stockleye, Johan H.C. Reiberc, Berend C. StoelcaDepartment of Pulmonology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
bDepartment of Medical Statistics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
cDivision of Image Processing, Department of Radiology, P.O. Box 9600, 2300 RC Leiden University Medical Center,
Leiden, The Netherlands
dDepartment of Respiratory Medicine, Gentofte University Hospital, Niels Andersens vej 65, DK-2900 Hellerup, Denmark
eDepartment of Respiratory Medicine, University Hospital, Edgbaston B15 2TH Birmingham, UK
fDepartment of Pulmonary Medicine, Malmo¨ University Hospital, 20502 Malmo¨, Sweden
gPulmonary Division, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
Received 9 February 2007; accepted 22 April 2007KEYWORDS
Airflow limitation;
Alveolar destruction;
Lung densitometryont matter & 2007
2007.04.016
thor. Tel.: +31 71
.stolk.long@lumc.Summary
In patients with airflow limitation caused by cigarette smoking, lung density measured by
computed tomography is strongly correlated with quantitative pathology scores of
emphysema, but the ability of lung densitometry to detect progression of emphysema is
disputed. We assessed the sensitivity of lung densitometry as a parameter of disease
progression of emphysema in comparison to FEV1 and gas transfer. At study baseline
and after 30 months we measured computed tomography (CT)-derived lung density,
spirometry and carbon monoxide diffusion coefficient in 144 patients with chronic
obstructive pulmonary disease (COPD) in five different centers. Annual change in lung
density was 1.31 g/L/year (CI 95%: 2.12 to 0.50HU, p ¼ 0.0015, 39.5mL/year (CI 95%:
100.0–21.0mL, p ¼ 0.2) for FEV1 (39.5mL) and 24.3 mmol/min/kPa/L/year for gas
transfer (CI 95%: 61.0–12.5 mmol/min/kPa/L/year, p ¼ 0.2). Signal-to-noise ratio (mean
change divided by standard error of the change) for the detection of annual change was 3.2
for lung densitometry, but 1.3 for both FEV1 and gas diffusion. We conclude that detectionPublished by Elsevier Ltd.
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Lung densitometry for emphysema 1925of progression of emphysema was found to be 2.5-fold more sensitive using lung
densitometry than by using currently recommended lung function parameters. Our results
support CT scan as an efficacious test for novel drugs for emphysema.
& 2007 Published by Elsevier Ltd.Introduction
Pulmonary emphysema is a component of chronic obstruc-
tive pulmonary disease (COPD), which has an increasing
prevalence worldwide.1 The forced expiratory volume in 1 s
(FEV1) is traditionally used to quantify disease progression in
COPD and emphysema.2 It is also seen as the most important
outcome parameter for the assessment of treatment
efficacy of new drugs for this condition.1 Over the past 10
years, only a few studies have been conducted on the
effects of medical treatment of emphysema. However, the
cessation of smoking has proved to be the only way to
achieve a clinically significant effect on FEV1.
3–6 A single
efficacy measure (such as FEV1) may not be the optimal
outcome parameter for the assessment of treatment effects
of the various disease components of COPD (such as
chronic bronchitis, small airways disease and emphysema)
in therapeutic trials of specific disease modifying drugs and
consequently, there is a need for more specific and sensitive
parameters.1
The introduction of computed tomography (CT) in the
field of medical imaging was a major step forward for the
diagnosis of emphysema.7 Cross-sectional studies on quanti-
tative aspects of CT images of the lung, demonstrated the
possibility of computerized detection of emphysema and
quantitative scoring.8–10 A common approach is to detect
the lung contour in the CT-data and to calculate the
frequency distributions of densities, expressed in Hounsfield
units, within the identified lung regions.
Based on the strong correlation between quantitative
pathological scores and CT-derived quantitative densitome-
try scores of emphysema in cross-sectional human studies,
the assessment of changes in lung density appears to be a
promising alternative to lung function parameters.8–10 The
aim of the present study was to assess in a multi-center
study, the natural progression of emphysema by measuring
change in lung density and changes in FEV1 and Kco (carbon
monoxide gas diffusion coefficient) and determine the
sensitivity of these measurements in a patient population
with a wide range of emphysema progression.Methods
Patient population
Five university hospital centers participated in this study
and recruited a total of 144 patients through advertisement.
Patients were included if they had been diagnosed with
emphysema by a high-resolution CT scan and had dyspnea on
exertion.11 Patients with concomitant disease that would
prevent the completion of study duration were excluded. All
available medication for COPD, including long-acting beta-
agonists and tiotropium bromide were allowed. None of thepatients diagnosed with homozygous type Z alpha-1-anti-
trypsin deficiency were receiving alpha-1-antitrypsin aug-
mentation therapy. The study was approved by the
institutional review board of each participating center.
Patients provided written informed consent.Study design
The study had a longitudinal design and consisted of two
visits, one at baseline and a second after 30 months. At each
visit a chest CT scan and post-bronchodilator pulmonary
function tests, including spirometry and carbon monoxide
gas transfer, were performed (see Characterization of
Subjects in online data supplement). Smoking status was
confirmed at start and end of the study by cotinine assay of a
urine sample.Computed tomography (CT)
Each of the five participating centers used a different CT
scanner. There were four multi-detector scanners (General
Electric, Marconi (now Philips), Siemens and Toshiba) and
one single detector scanner (Philips AVE). All CT scanners
were calibrated for water (with a standard phantom) and
for air. In addition, a dedicated phantom was used to check
the constancy of the CT scanner during the study period
(see CT Quality Control Using Phantom Scans in online data
supplement).
During each visit, every patient was scanned twice, at
different inspiration levels (one scan after breath hold at
full inspiration and one after a voluntary lower level of
inspiration). Images were acquired in the supine position
with CT settings that allow low radiation dose and high
density resolution.12 A specific acquisition protocol for each
scanner has been provided elsewhere.13 Typically, the
acquisition protocol comprised 140 kVp, 40mAs, pitch factor
1.5, 5mm collimation, reconstructed with a slice thickness
of 5 and 2.5mm increment and a smooth reconstruction
filter for both patients and the phantom.Densitometry
All CT images were analyzed using densitometry with Pulmo-
CMS (Medis, medical imaging systems, Leiden, the Nether-
lands).13 The 15th percentile point (Perc15) was chosen in
this study for the assessment of emphysema progression as
previously recommended.12 The Perc15 is defined as the
threshold value in Hounsfield units (HU) for which 15 percent
of all lung voxels has a lower density value.
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Analysis of outcome parameters was performed for each
participating site, using a mixed-effects regression model
with density as outcome and lung volume and time of CT
scans as both fixed and random (per patient) variables. Lung
volume derived from the CT images was log-transformed to
achieve normal distribution, and mean-centered to improve
numerical stability. An error distribution with unstructured
correlation was used in order to correct for autocorrelation
(see Volume Correction in online data supplement).
The progression estimates for each site and their standard
errors were then combined using meta-analysis with the
software package ‘‘R’’ (the R-project, Statistics Department
of the University of Auckland, NZ) with random effects, to
account for possible heterogeneity in CT results due to
study-site specific differences in either the patient popula-
tions or CT equipment.14
The meta-analysis approach was also used for progression
in FEV1 and Kco, but the site-specific estimates and standard
errors were obtained simply by calculating mean and
standard errors of the standardized (by the number of years
of follow-up) differences between follow-up and baseline
for each site.
The signal-to-noise ratio in detecting the annual change
of an outcome parameter, was defined as the mean change
divided by the standard error of the change, and was
calculated for densitometry, FEV1 and Kco.
5
Data are presented as mean and 95% confidence intervals
where appropriate. The correlation between parameters
was calculated by Pearson’s correlation coefficient. All tests
were two-sided, for which an alpha level of 0.05 was
considered to indicate statistical significance.
Results
Baseline results
A total of 144 patients were recruited for the study
(Table 1a). The correlation between the baseline CO diffusion
coefficient and lung density was 0.639 (po0.001) and 0.586
between baseline FEV1 and lung density (po0.001) (Table 2).
The correlation between the CO diffusion coefficient and
baseline FEV1 was 0.413 (po0.001) (Table 2). There was no
correlation between age and baseline lung density (0.069,
p ¼ 0.414). The average time between diagnosis of emphy-
sema and first study visit was 371 year.
Progression of emphysema
During the study period a number of patients were lost
for follow-up. Ten patients died, four patients had lung
transplantation or lung volume reduction surgery and 19
patients refused to attend for follow-up. The data of a single
site that contributed 23 patients to the study could not be
used (see Figure E1-A and E1-B in online data supplement).
Baseline patient characteristics of the remaining 87 patients
are shown in Table 1b.
Lung density decreased significantly by 1.31 g/L/year
(CI 95%: 2.12 to 0.50 HU, p ¼ 0.0015, Fig. 1), while
FEV1 decreased by 39.5mL/year (CI 95%: 100.0–21.0mL,p ¼ 0.2, Fig. 2) and the gas diffusion coefficient by
24.3 mmol/min/kPa/L/year (CI 95%: 61.0–12.5 mmol/min/
kPa/L/year, p ¼ 0.2, Fig. 3 and Tables 2 and 3). When the
study population was divided into subjects with type ZZ
alpha-1-antitrypsin deficiency and non-ZZ deficiency, the
decrease in FEV1 and Kco did not differ significantly between
groups (Table 4).
The signal-to-noise ratio (defined as the mean change
divided by the standard error of the change) in detecting
annual change was 3.2 for lung densitometry, but 1.3 for
both FEV1 and the gas diffusion coefficient (Table 3).
Baseline results and progression
There was a weak correlation between FEV1 and lung density
at study baseline and subsequent annual change in gas
diffusion (r ¼ 0.213, p ¼ 0.027; r ¼ 0.215, p ¼ 0.025, re-
spectively). The annual change in lung density or FEV1 was
independent of the severity of emphysema at study baseline
when expressed as baseline values for lung density, FEV1 or
CO diffusion coefficient (Table 2). In addition, changes in
density and changes in lung function (FEV1 or diffusion
coefficient) were not, or only weakly linked (Table 2). No
correlation was found between changes in lung density and
age (r ¼ 0.040, p ¼ 0.711).
Discussion
In COPD and emphysema, the rate of FEV1 decrease is
traditionally used to quantify disease progression and the
efficacy of new drugs.2 A single surrogate measure for
multiple phenotypic disease components of COPD (such as
chronic bronchitis, small airways disease and emphysema)
may not be optimal for assessing treatment effects in
therapeutic trials with specific disease-modifying drugs.
Consequently, there is a challenge to develop emphysema-
specific and more sensitive parameters.15 We report that
lung density is 2.5-fold more sensitive than FEV1 or gas
diffusion to detect progression of emphysema.
Few randomized placebo-controlled medicinal interven-
tion strategies for COPD and only one intervention strategy
for emphysema showed sensitivity for change in the rate of
decline in FEV1.
3–6 Whereas FEV1 is a measure of both airway
wall thickening and collapse of the small airways due to loss
of elastic recoil in the lung lobes, lung density is a more
specific reflection of airspace enlargement by alveolar
destruction present in emphysema.8–10,16 This difference in
pathological correlation may explain the poor correlation
between the rate of decrease in lung density and FEV1 or Kco
in our study population (Table 2). Based on the sensitivity (or
signal-to-noise ratio) of our progression parameters, this
lack of correlation can be explained by significant differ-
ences in the signal-to-noise ratios of the three measure-
ments.17 It has been demonstrated that measurements such
as FEV1 and Kco are relatively insensitive to changes in end-
stage COPD and emphysema.2,4 Yet, the histopathology of
end-stage disease still contains signs of active inflammation
rather than of resolution.18 In contrast to FEV1 and Kco, lung
densitometry is able to detect disease progression in severe
emphysema as supported by our finding that decreases
in lung density were not associated with the severity of
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Table 1a Characteristics of 144 patients at study baseline.
Absolutea Predicted (%) Range (% predicted)
Sex male/female 75/69 – –
Age [yr] 58.5 (11.1) – –
Alpha-1-antitrypsin phenotype (ZZ/non-deficient) 79/65 – –
Smoking status [c/e/n]b 42/70/32 – –
FEV1 [L] 1.59 (0.9) 54.8 (26.9) 20–115
FEV1/FVC [%] 0.43 (0.12) 24–86
Kco [mmol/min/kPa/L] 0.96 (0.4) 63.4 (22.5) 19–109
Urine cotinine assay positive 37/144 – –
Inhaled corticosteroid use 122/144 – –
Inhaled LABA usec 135/144 – –
Inhaled tiotropium use 103/144 – –
aMean values (SD).
bc/e/n means current/ex/never smoker.
cLong-acting beta agonist.
Table 1b Characteristics of 87 patients at study baseline, included in analysis of progression.
Absolutea Predicted (%) Range (% predicted)
Sex male/female 44/43 – –
Age [yr] 58.6 (10.4) – –
Alpha-1-antitrypsin phenotype (ZZ/non-ZZ) 53/34 – –
Smoking status [c/e/n]b 24/47/16 – –
FEV1 [L] 1.45 (0.6) 50.2 (19.2) 20–115
FEV1/FVC [%] 0.45 (0.13) 24–86
Kco [mmol/min/kPa/L] 0.90 (0.3) 60.8 (19.8) 19–109
Urine cotinine assay positive 24/87 – –
Inhaled corticosteroid use 79/87 – –
Inhaled LABA usec 85/87 – –
Inhaled tiotropium use 84/87 – –
aMean values (SD).
bc/e/n means current/ex/never smoker.
cLong-acting beta agonist.
Lung densitometry for emphysema 1927emphysema present at study baseline (expressed by FEV1
or Kco). Indeed, the rationale behind the development of CT
densitometry was to overcome rather than reflect the
deficiencies of FEV1 and the lack of correlation between
these two should not necessarily be interpreted as dis-
advantageous. On the contrary, it supports the concept that
lung densitometry is a more appropriate method for
monitoring progression of emphysema.
The calculation of the progression of lung density
decrease is subject to various confounders. Firstly, the
relationship between lung density and the inhaled volume of
air in the lung during the scan must be accounted for.19 In
addition lung density is dependent on lung size. Large lungs
have a lower density than small lungs.19 Therefore, in order
to compare individuals, lung densities need to be corrected
for lung volume.20 Secondly, CT scanners from different
vendors use different software for image-reconstruction
which results in different density distributions.21 We
addressed these issues in a separate study by comparing
three different mathematical models to characterize theoptimal correction of density for lung volume (submitted for
publication). We found that a combined estimate approach
was needed to allow pooling of the mean of density values of
four study centers.
Our study population had a wide range of values in FEV1
and CO diffusion capacity indicating a range from mild to
severe emphysema. The latter may also explain the
relatively low annual decrease in FEV1 of 45mL measured
over a relatively short period of time.22 The contribution of
emphysema to the rate of increase of airflow limitation
remains uncertain, mainly because of the absence of
longitudinal studies delineating the alveolar and airway
components that contribute to FEV1 values.
In cross-sectional studies, measurements of CO diffusion
capacity correlate well with pathological scores of emphy-
sema and therefore CO diffusion measurements qualify as a
progression parameter for emphysema.9 Few previous
studies have followed individuals with regular measure-
ments of gas transfer for sufficiently long periods of time to
be able to describe the rate of decrease in patients with
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Figure 1 Progression of emphysema measured using densito-
metry. Annual change in lung density (g/L) of patients with
emphysema measured at four different study centers. Values
are mean change and 95% confidence interval. The combined
estimate represents the mean change of patients of all four
sites and its 95% confidence interval. The weight with which the
data of each site contribute to the combined estimate is
represented by the size of the square markers.
Figure 2 Progression of emphysema measured using FEV1.
Annual change in FEV1 (mL) of patients with emphysema
measured at four different study centers. Values are mean
change and 95% confidence interval. The combined estimate
represents the mean change of patients of all four sites and its
95% confidence interval. The weight with which the data of
each site contribute to the combined estimate is represented by
the size of the square markers.
Figure 3 Progression of emphysema measured using CO
diffusion capacity. Annual change in Kco (mmol/min/kPa/L) of
patients with emphysema measured at four different study
centers. Values are mean change and 95% confidence interval.
The combined estimate represents the mean change of patients
of all four sites and its 95% confidence interval. The weight with
which the data of each site contribute to the combined
estimate is represented by the size of the square markers.
J. Stolk et al.1928moderate-to-severe emphysema.5,23,24 We designed our
study to last for 30 months, a period of time that is likely
to be the maximal duration that is acceptable for both
patients and pharmaceutical companies to investigate a
beneficial effect of a new investigational drug. In addition,
little is known about how the direction of change in CO
transfer relates to change in FEV1. In one small study,
carried out over 22 years, men with an initially reduced CO
transfer coefficient had significantly faster subsequent
decrease in FEV1.
24 In contrast, analysis of 543 subjects
who participated in the Tucson epidemiology study revealed
that the slope of DLco was not significantly different
between smokers and never smokers.3 Moreover, higher
results for FEV1 at study baseline were not associated
with different DLco slopes.
3 We found that changes in Kco
(DLco proportional to ventilating lung area) and changes in
FEV1 correlated only very weakly with baseline FEV1 and
baseline Kco, respectively (Table 2). In addition, the changes
in FEV1 and the changes in Kco correlated weakly with
baseline lung density. However, none of the changes with
time correlated with each other (Table 2). Taken together,
the published results and our own findings indicate that
change in gas diffusion capacity, airflow and lung density in
patients with emphysema occur independently from the
level measured at study baseline.
This study has some limitations: patients were selected
based on the presence of emphysema identified using high
resolution CT. Because the gold standard for emphysema
diagnosis is based on pathological examination of lung
tissue, the presence of emphysema seen by a pathologist
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Table 2 Pearson correlations (including p-value) of density (Perc15) and lung function parameters (FEV1 and Kco).
Baseline FEV1 Baseline Kco Change Perc15 Change FEV1 Change Kco
Baseline Perc15 0.586 (p50.001) 0.639 (p50.011) 0.049 (p ¼ 0.652) 0.182 (p ¼ 0.054) 0.215 (p ¼ 0.025)
Baseline FEV1 0.413 (p50.001) 0.123 (p ¼ 0.257) 0.043 (p ¼ 0.655) 0.213 (p ¼ 0.027)
Baseline Kco 0.088 (p ¼ 0.420) 0.175 (p ¼ 0.066) 0.134 (p ¼ 0.165)
Change Perc15 0.166 (p ¼ 0.123) 0.083 (p ¼ 0.451)
Change FEV1 0.049 (p ¼ 0.615)
Table 3 Progression of emphysema of 87 patients.
Center Number of patients Change in density
(g/L/year)
Change in FEV1
(mL/year)
Change in Kco (mmol/
min/kPa/L/year)
1 19 2.15 (0.41) 24.1 (45.4) 7.0 (46.4)
2 34 1.33 (0.24) 70.1 (61.9) 45.9 (57.9)
3 17 1.68 (0.62) 31.7 (78.9) 23.8 (23.6)
4 17 0.37 (0.21) 44.6 (83.7) 32.5 (58.5)
Combined estimate of
centers 1–4
87 1.31 (0.40) 45.8 (30.9) 30.9 (18.7)
95% CI (2.12; 0.50) (100.0; 21.0) (61.0; 12.5)
P-value 0.0015 0.2 0.2
Signal/noise ratio 3.2 1.3 1.3
Values of change are presented as mean and (standard error). FEV1, forced expiratory volume in 1 s; Kco, carbon monoxide gas diffusion
coefficient; 95% CI, 95% confidence interval, sensitivity defined as mean divided by standard error of mean.
Tabel 4 Progression of emphysema related to alpha-1-antitrypsin deficiency.
Alpha-1-antitrypsin
fenotype
Number of patients Change in density
(g/L/year)
Change in FEV1
(mL/year)
Change in Kco (mmol/
min/kPa/L/year)
ZZ 53 NA 48.2 (70.6) 29.5 (49.3)
Non-ZZ, non serum
deficient
33 NA 42.1 (63.7) 32.9 (54.8)
Values of change are presented as mean and standard deviation. NA, not applicable. Similar comparison of analysis for density values
could not be performed reliably due to the significant heterogeneity of the density data between study centers.
Lung densitometry for emphysema 1929and the characteristics of emphysema seen on HRCT by a
radiologist may not always be the same.8,9,11 Therefore, it is
possible that some of our participants may have been
misclassified as emphysema patients. Likewise, the correla-
tion between the pathological score for emphysema and
lung density scores of CT images published in the literature
is at best 0.77.9 The latter suggests that not all patients with
a low Perc15 value have emphysema to the same extent.
Therefore, the estimates of progression of emphysema
may be subject to some error although if anything this
may underestimate the true sensitivity of the density
progression.
Finally, we assumed that progression of our lung density
parameter is linear over time. This assumption was based on
the results of a previous study, in which annual CT and lung
densitometry showed almost linear decrease in lung density
in 28 placebo-treated patients.5 The general applicability ofthe data and methodology to all patients with emphysema
could be debatable. However, subgroup analysis showed that
there was no significant difference between emphysema
patients with and those without type Z alpha-1-antitrypsin
deficiency when analyzed for decrease in FEV1 or Kco.
Similar comparison of analysis for density values could not
be performed reliably due to a combination of low patient
numbers and the significant heterogeneity of the density
data between study centers.
In summary, we studied a group of patients with a wide
range of lung function impairment and found that assess-
ment of emphysema progression was more sensitive when
CT-derived lung densitometry was used compared to FEV1
and measurements of gas transfer. The rate of lung density
decrease was independent of the severity of emphysema at
study baseline. The results support this methodology for
testing the efficacy of novel drugs for emphysema.
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